# POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation

> **NCT06409039** · — · ENROLLING_BY_INVITATION · sponsor: **Azienda Ulss 2 Marca Trevigiana** · enrollment: 80 (estimated)

## Conditions studied

- Endometrial Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06409039
- **Lead sponsor:** Azienda Ulss 2 Marca Trevigiana
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-09-04
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409039, "POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06409039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*